NEO vs SLNO vs CDNA vs NTRA vs EXAS

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 10. 1% for NeoGenomics, Inc. (NEO). Soleno Therapeutics, Inc. (SLNO) offers the better valuation at 135. 9x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate NeoGenomics, Inc. (NEO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Soleno Therapeutics, Inc.

is actually cheaper at 13. 9x.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +104. 4%, compared to -74. 6% for CareDx, Inc (CDNA). Over 10 years, the gap is even starker: NTRA returned +1731% versus SLNO's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at -0.

05β versus NeoGenomics, Inc. 's 1. 37β — meaning NEO is approximately -3047% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Soleno Therapeutics, Inc. (SLNO) carries a lower debt/equity ratio of 1% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus 10. 1% for NeoGenomics, Inc. (NEO). On earnings-per-share growth, the picture is similar: Soleno Therapeutics, Inc. grew EPS 108. 9% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Soleno Therapeutics, Inc.

(SLNO) is the more profitable company, earning 11. 0% net margin versus -14. 9% for NeoGenomics, Inc. — meaning it keeps 11. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SLNO leads at 7. 9% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — SLNO leads at 98. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Soleno Therapeutics, Inc.

(SLNO) trades at 13. 9x forward P/E versus 582. 8x for Exact Sciences Corporation — 568. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NEO: 70. 4% to $19. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

05), +1390% 10Y return). Both have compounded well over 10 years (EXAS: +1390%, NEO: +42. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NEO is a small-cap quality compounder stock; SLNO is a small-cap quality compounder stock; CDNA is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; EXAS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.